The first human study using gene transfer to treat erectile dysfunction (ED) shows promising results and suggests the potential for using the technology to treat overactive bladder, irritable bowel syndrome and asthma, according to the researchers.

“In the small pilot study, this new therapy was well tolerated and safe,” said George Christ, Ph.D., senior researcher and a professor at the Institute for Regenerative Medicine at Wake Forest University School of Medicine. “It provides evidence that gene transfer is a viable approach to treating ED and other diseases involving smooth muscle cells.“

The results of the study, which included 11 men with ED, are reported in Human Gene Therapy. The technology was developed by Christ and Arnold Melman, M.D., when they worked together at Albert Einstein College of Medicine in the Bronx, New York.

Unlike traditional gene therapy, the gene transfer approach being pioneered by Christ and Melman does not change the DNA or genetic code of cells. Instead, small pieces of DNA reach the nuclei of cells and this causes them to increase production of particular proteins. These proteins help relax smooth muscle cells, the type of muscle found in the penis as well as in hollow organs such as the bladder. Relaxing the tissue allows the penis to fill with blood and become erect.

Previous research has shown that more than 50 percent of men between 40 and 70 years old and 70 percent over age 70 may have ED. The new therapy is a potential alternative to oral medications, such as generic viagra, which are not effective for an estimated 30 to 40 percent of men with ED.

A possible advantage of gene transfer is that a single treatment could last for months. In the current study, improvements were maintained through the 24 weeks of study.

The study was conducted from May 2004 to May 2006 at Mount Sinai School of Medicine and New York University School of Medicine. Men ranged from 42 to 80 years old with a mean age of 59. Six subjects were white, four were black and one was Hispanic. In half of the subjects, the cause of ED was diabetes or cardiovascular disease – both of which can interfere with the ability of smooth muscle cells to relax.

The primary goal of the study was to determine the safety and tolerability of the new therapy. However, the results also showed that at the highest doses, men reported highly significant improvements in erectile function.

The DNA segments – mixed into plasma – were injected into the corpus cavernosum, expandable tissue along the length of the penis that fills with blood during erection. A variety of clinical and laboratory tests were used to assess safety. In addition, effectiveness was measured using the International Index of Erectile Function scale, a questionnaire that is commonly used to measure ED. Patient responses were validated by their partners.

Researchers identified no safety issues with the treatment. Participants who received the highest two doses had apparent sustained improvements in ED as measured by the questionnaire. The researchers said that a larger study that includes a “control” group treated with a placebo is needed to confirm the safety and effectiveness of the treatment.

Other researchers on the project were Melman, Natan Bar-Chama, M.D., with Mount Sinai School of Medicine, Andrew McCullough, M.D., with New York University School of Medicine, and Kelvin Davies, Ph.D., with Albert Einstein College of Medicine.

The technology is being developed by Ion Channel Innovations (ICI), a development stage biotechnology company, in which Christ and Melman are co-founders and directing members. The therapy is known as ion channel therapy because the proteins it targets are potassium channels, “gates” within cells critical for contraction and relaxation of smooth muscle.

At the Wake Forest Institute for Regenerative Medicine, Christ is continuing to pursue the therapy in collaboration with ICI, and is also exploring the potential of combining gene transfer with traditional oral medications to further increase the clinical utility of the technology. The Albert Einstein College of Medicine at Yeshiva University owns the ICT patents and has granted the company exclusive, worldwide rights.

The kids. The job. The house. The cell phone, blackberry and email. With all the responsibilities many women juggle, there is often no time for romance, and in many cases, even less desire. Well over a third (40 – 45%) of adult women experience at least one symptom of sexual dysfunction, and few feel they can talk about it.

UCSD researchers are working to change the condition and this way of thinking. “Women who have sexual dysfunction should realize this may be a treatable condition, not just a personal problem,” says Thuy-Tien L. Dam, M.D. of the UCSD Department of Family and Preventive Medicine. “Many women don’t know that other women experience this too, and that it might be a diagnosable disorder called Hypoactive Sexual Desire Disorder or HSDD.”

Viagra for women

Dam, clinical director at UCSD Prevention Studies, is conducting a clinical trial to see whether an investigational drug is safe and effective for women with low sexual desire. HSDD is the most common form of female sexual dysfunction, characterized by decreased sexual thoughts and feelings as well as a loss of desire for sex. About 17% to 55% of women have low levels of sexual interest, depending on age. Canadian female viagra is scientifically formulated to treat female sexual dysfunction.

“Candidates for the study are women who have desire problems; women who once had a healthy sex-drive who now notice a big difference in desire level, for some unknown reason,” says Dam. “If we can understand the physiologic process of what’s happening, we can tailor the treatment specifically for that.”

Studies have shown that erectile dysfunction in men is sometimes caused by a physiologic problem, such as reduced blood flow. There is a school of thought that perhaps physiologic changes in the female brain may be associated with female sexual dysfunction.

While male erectile dysfunction is widely known, publicly discussed and treated, the U.S. Food and Drug Administration has not approved any investigational drugs for treating similar disorders in women. This study is an important step in the therapeutic options to help women regain a satisfactory sex life, and to be able to talk about it, said Dam.

Women who may qualify for this study:

• are premenopausal, 18 years of age and older;
• are using a medically approved form of birth control or are surgically sterile;
• are not nursing or pregnant;
• have experienced a loss of sexual desire for at least 6 months;
• have been in a stable, heterosexual, monogamous relationship for at least 1 year;
• are not taking an antidepressant.

Female Enhancement

Approximately 30 women will be enrolled at UCSD Prevention Studies. A total of 1,400 women are expected to enroll at 75 sites in the Unites States and Canada.

Canadian generic viagra online
CORTICOSTEROID THERAPY
Maternal corticosteroid treatment with betamethasone and dexamethasone has been shown in several controlled trials to decrease the incidence of respiratory distress syndrome. Antenatal corticosteroid therapy decreased the risk of respiratory distress syndrome, intraventricular hemorrhage, and mortality in infants born prematurely. Antenatal therapy with corticosteroids should be considered for all fetuses at risk for preterm delivery between 24 and 34 weeks of gestational age, regardless of race, gender, or availability of surfactant therapy. Antenatal corticosteroids should be considered in the presence of preterm PROM in pregnancies less than 30-32 weeks of gestation unless there is evidence of clinical chorioamnionitis.
There has been hesitation to use corticosteroids in some patients because of the impression that delivery will occur before a full course of therapy (ie, less than 24 hours). However, treatment with corticosteroids for less than 24 hours still appears to be associated with a significant reduction in neonatal mortality, respiratory distress syndrome, and intraventricular hemorrhage. The most commonly used regimens of antenatal corticosteroids would appear to be either two doses of 12 mg of betamethasone given intramuscularly 24 hours apart or four doses of 6 mg of dexamethasone intramuscularly 12 hours apart.
METHOD OF DELIVERY
Retrospective studies show that the singleton breech of less than 32-34 weeks of gestation or weighing less than 1,500 g has less morbidity and mortality if delivered by the cesarean method, particularly if the breech presents as a footling. There are no convincing data to indicate that cesarean delivery is indicated for cephalic presentations if labor is progressing in a normal fashion. Factors associated with intraventricular hemorrhage are the prematurity of the fetus, shock, and respiratory distress syndrome, but not the mode of delivery for cephalic presentations.